The biotech sector in April 2026 is seeing a resurgence driven by clinical milestones, FDA approvals, and a renewed interest in growth-oriented assets following a period of valuation compression. "Cheap" biotech stocks currently fall into two main categories: those with low nominal share prices (under $10) and larger-cap companies trading at historically low valuation multiples. Promising Stocks Under $10
: Recently transitioned to a commercial-stage firm with an FDA-approved cancer drug; analysts see significant upside potential in 2026. cheap biotech stocks to buy
: Working on targeted radiotherapy; analysts project significant revenue growth in 2025-2026 if Phase 3 trials succeed. Undervalued Mid-to-Large Cap Leaders The biotech sector in April 2026 is seeing
: A profitable firm trading at roughly 14 times earnings, well below the sector average of 26. : A high-risk, high-reward mRNA play with major
: Focused on oncology with a high-performing lead drug, Cabometyx, and an estimated three-year revenue CAGR of 11.6%.
: A high-risk, high-reward mRNA play with major Phase 2 study results for cystic fibrosis expected in the first half of 2026.